study of ds-8201a in her2-low, unresectable and/or metastatic breast cancer
Published 4 years ago • 1K plays • Length 2:43Download video MP4
Download video MP3
Similar videos
-
3:19
study of targeted therapy for her2-positive metastatic breast cancer
-
49:09
metastatic breast cancer forum 2018: her2-positive breast cancer | dana-farber cancer institute
-
1:36
is her2-low a distinct subtype of breast cancer?
-
4:31
study of atezolizumab with pertuzumab and trastuzumab in her2- positive metastatic breast cancer
-
4:27
study of immunotherapy combinations for patients with her2-positive metastatic breast cancer
-
1:40
her2-low is not a distinct subtype in inflammatory breast cancer
-
1:22
atempt breast cancer study | dana-farber cancer institute
-
1:16
her2-low expression in breast cancer
-
2:13
remaining questions surrounding her2-low breast cancer – how low can you go?
-
33:41
clinical trials for metastatic breast cancer: what you should know | dana-farber cancer institute
-
0:59
treatment for early stage her2 breast cancer | dana-farber cancer institute
-
1:00:28
extending the benefits of targeting her2 in breast cancer | dana-farber cancer institute
-
1:09
the exciting new field of her2-low breast cancer
-
4:59
study of saci-io for hormone receptor positive metastatic breast cancer
-
5:21
study of neratinib for patients with her2-positive breast cancer with brain metastases
-
2:21
adcs for the treatment of her2-low breast cancer
-
6:29
study of palbociclib after cdk & endocrine therapy in er /her2- metastatic breast cancer
-
55:21
beyond boston 5th annual luncheon | dana-farber cancer institute
-
8:02
what are the treatment options for early stage breast cancer?